Hexasol Injection 300mg/20mg mL (250 ml)

Hexasol Injection an antibiotic, non-steroidal anti-inflammatory solution for the treatment of bacterial pneumonia associated with Pasteurella spp.; and for the control of associated pyrexia in beef and non-lactating dairy cattle. Each ml contains 300 mg of oxytetracycline and 20 mg of flunixin.

Indications

For the treatment of bacterial pneumonia associated with Pasteurella spp. and for the control of associated pyrexia in beef and non-lactating dairy cattle.

View Hexasol Drug Facts Sheet.

Administer Hexasol Injection once as an intramuscular or subcutaneous injection of 1 mL per 22 lb body weight (13.6 mg oxytetracycline and 0.9 mg flunixin per lb BW). Do not administer more than 10 mL per injection site (1 to 2 mL per site in small calves). Hexasol Injection is recommended where retreatment of calves and yearlings is impractical due to husbandry conditions, such as cattle on range, or where their repeated restraint is inadvisable.

Caution:

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Contraindication:

Do not use in animals showing hypersensitivity to either flunixin meglumine or oxytetracycline.

Warnings & Precautions:

Withdrawal Periods and Residue Warnings

Residue Warnings: Discontinue treatment at least 21 days prior to slaughter of cattle. This drug product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. Use of dosages other than those indicated may result in residue violations.

Exceeding the highest recommended level of drug per pound of bodyweight per day, administering more than the recommended number of treatments, and/or exceeding 10 mL intramuscularly or subcutaneously per injection site in beef cattle and non-lactating dairy cattle may result in antibiotic residues beyond the withdrawal time.

Antibacterial Warnings

Use of antibacterial drugs in the absence of a susceptible bacterial infection is unlikely to provide benefit to treated animals and may increase the risk of the development of drug-resistant pathogenic bacteria.

As with all antibiotic preparations, use of this drug may result in overgrowth of non-susceptible organisms, including fungi. The absence of a favorable response following treatment or the development of new signs or symptoms may suggest an overgrowth of non-susceptible organisms. If superinfections occur, the use of this product should be discontinued and appropriate specific therapy should be instituted. Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving Hexasol Injection in conjunction with penicillin.

User Safety Warnings:

Not for use in humans. Keep out of reach of children. The Material Safety Data Sheet (MSDS) contains more detailed occupational safety information. To obtain an MSDS contact Norbrook at 1-866-591-5777.

Animal Safety Warnings & Precautions:

At the first sign of any adverse reaction, discontinue use of the product. Some of the reactions may be attributable either to anaphylaxis (an allergic reaction) or to cardiovascular collapse of unknown cause.

Shortly after injection, treated animals may have transient hemoglobinuria resulting in darkened urine. Intramuscular injection in the rump area may cause mild temporary lameness associated with swelling at the injection site.

As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse effects varies with the individual patient. Patients at greatest risk for adverse events are those that are dehydrated, on diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Since many NSAIDs possess the potential to produce gastrointestinal ulceration, concomitant use of Hexasol Injection with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided or closely monitored.

Flunixin is a cyclo-oxygenase inhibitory NSAID, and as with others in this class, adverse effects may occur with its use. The most frequently reported adverse effects have been gastrointestinal signs. Events involving suspected renal, hematologic, neurologic, dermatologic, and hepatic effects have also been reported for other drugs in this class.

Not for use in animals intended for breeding purposes. The effects of oxytetracycline and flunixin on bovine reproductive performance, pregnancy, and lactation have not been determined. NSAIDs are known to have potential effects on both parturition and the estrous cycle. There may be a delay in the onset of estrus if flunixin is administered during the prostaglandin phase of the estrous cycle. The effects of flunixin on imminent parturition have not been evaluated in a controlled study. NSAIDs are known to have the potential to delay parturition through a tocolytic effect.

Other Warnings:

Hexasol Injection, when administered as directed, may induce a transient reaction at the site of injection and underlying tissues that may result in trim loss of edible tissue at slaughter.

Adverse Reactions:

At the first sign of any adverse reaction, discontinue use of the product. Reports of adverse reactions associated with oxytetracycline administration include injection site swelling, restlessness, ataxia, trembling, swelling of eyelids, ears, muzzle, anus and vulva (or scrotum and sheath in males), respiratory abnormalities (labored breathing), frothing at the mouth, collapse and possibly death. Some of these reactions may be attributed either to anaphylaxis (an allergic reaction) or to cardiovascular collapse of unknown cause. After flunixin administration in cattle, anaphylactic-like reactions have been reported, some of which have been fatal, primarily following intravenous use.

Storage:

Store at 59° to 86°F (15° to 30°C)